206 results on '"Goffin, John R"'
Search Results
2. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
3. Risk Perception Among a Lung Cancer Screening Population
4. A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer
5. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219
6. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer
7. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial
8. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
9. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study
10. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency
11. Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population
12. Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness
13. Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study
14. Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer
15. Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
16. Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).
17. Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
18. Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
19. Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
20. Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”
21. Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.
22. Early stopping rules in oncology: Considerations for clinicians
23. Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses—Reply
24. Cost-effectiveness of Lung Cancer Screening in Canada
25. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
26. Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system
27. DEALE-ing with lung cancer and heart failure
28. Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis
29. The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model
30. Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model
31. Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
32. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
33. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model
34. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
35. CT-19-0133.R2_Appendix_clean – Supplemental material for Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study
36. Additional file 1 of Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population
37. Additional file 2 of Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population
38. Management Options: Metastatic Colorectal Carcinoma
39. Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer
40. Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
41. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma
42. Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study
43. CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
44. Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials
45. A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials
46. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
47. CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
48. A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
49. A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
50. American Society of Clinical Oncology Policy Brief: FDA’s Regulation of Electronic Nicotine Delivery Systems and Tobacco Products
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.